期刊文献+

氯沙坦联合吲达帕胺治疗高血压临床疗效观察 被引量:3

Losartan indapamide Clinical efficacy of treatment of hypertension
下载PDF
导出
摘要 目的探讨氯沙坦联合吲达帕胺治疗高血压临床效果。方法对52例高血压患者给予氯沙坦联合吲达帕胺药物治疗,疗程为两个月,并结合社区医疗,实施以合理膳食和健康教育等的非药物治疗,疗程结束,评价其治疗效果。结果52例高血压患者中,显效33例,有效17例,无效2例,总有效率为96.1%。结论氯沙坦为血管紧张素受体拮抗剂(ARB),吲达帕胺为利尿剂,两者配伍,临床疗效佳。并积极配合社区医生开展的健康教育,减轻体质量和限制钠盐摄入效果更佳。 Objective Of Losartan indapamide clinical effect of treatment of hypertension.Methods 52 cases of hypertension were treated with Losartan indapamide therapy, treatment for two months, combined with community health, the implementation of a reasonable diet and health education, non-drug treatment, the end of treatment and evaluate its therapeutic effect.Results 52 patients with hypertensive patients, 33 cases markedly effective in 17 cases, 2 cases, total effective rate was 96.l%.conclusions Anglotensin receptor antagonist losartan (ARB), a diuretic, indapamide, the two compatibility, good clinical efficacy. And to actively cooperate with the community doctors to carry out health education, reducing body weight and limit salt intake better.
作者 陈雄
出处 《中国中医药咨讯》 2011年第6期39-40,共2页
关键词 高血压 氯沙坦 吲达帕胺 社区治疗 Hypertension losartan indapamide community treatment
  • 相关文献

参考文献4

二级参考文献26

  • 1张静,刘洋.高血压病人的用药指导[J].社区医学杂志,2006,4(08X):24-26. 被引量:12
  • 2MANCIA G, DEBACKER G, DOMINICZAK A, et al. 2007 Guidelines for the management of arterial hypertension : the task force for the management of arterial hypertension of the european society of hypertension (ESH) and of the european society of cardiology (ESC) [J]. Eur Heart J, 2007,28(12) :1462 - 1536. 被引量:1
  • 3MATCHAR D B, MCCRORY D C, ORLANDO L A, et al. Systematic review : comparative effectiveness of angiotensin- converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension [ J ]. Ann Intern Med, 2008,148(1) :16-29. 被引量:1
  • 4SAWADA T, TAKAHASHI T, YAMADA H, et al. Rationale and design of the Kyoto Heart Study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events [J]. Journal of Human Hypertension, 2009, 23: 188- 195. 被引量:1
  • 5MOCHIZUKI S, DAHLOF B, SHIMIZU M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease ( Jikei Heart Study) : a randomised, open- label, blinded endpoint morbiditymortality study [ J]. Lancet,2007,369 : 1431 - 1439. 被引量:1
  • 6ZHU J R, FUJITA T, SHIMAMOTO K, et al. Implication of clinical studies for the Asian population: focus on Chinese/Asian population[J]. J Clin Pract, 2006, 60 (Suppl 150) : 14 - 16. 被引量:1
  • 7LINDHOLM L H, CARLBERG B, SAMUELSSON O. Shold β blockers remain first choice in the treatment of primary hypertension? a meta-analysis [ J ]. Lancet, 2005, 366 ( 9496 ) : 1545 - 1553. 被引量:1
  • 8BANGALORE S, PARKAR S, GROSSMAN E, et al. A meta-analysis of 94 492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus [ J ]. Am J Cardiol, 2007, 100 ( 8 ) : 1254 - 1262. 被引量:1
  • 9DAHLOF B, SEVER P S, POULTER N R, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) : a muhicentre randomised controlled trial [ J ]. Lancet,2005,366 (9489) : 895 - 906. 被引量:1
  • 10WILLIAMS B, LACY P S, THOM S M, et al. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study [ J ]. Circulation, 2006,113 (9) : 1213 - 1225. 被引量:1

共引文献56

同被引文献27

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部